Audited Standalone and Consolidated Financial Results for the fourth quarter and financial year ended on March 31, 2026
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Concord Biotech reported standalone revenue of Rs 1,05,507.10 lakhs for FY26, down 12% from Rs 1,20,008.69 lakhs in FY25. Profit after tax fell to Rs 26,326.67 lakhs from Rs 37,296.44 lakhs, a decline of ~29%, impacted by lower revenue and higher material/employee costs. The company recognised an exceptional charge of Rs 327.54 lakhs due to the statutory impact of new labour codes. The Board recommended a dividend of Rs 7.55 per share. Auditors BSR & Co. LLP issued an unmodified opinion. The company also appointed a new Internal Auditor, Cost Auditor, and an Additional Independent Director (Mrs. Ekta Gupta).
The sharp ~12% revenue decline and ~29% PAT decline are concerning for shareholders. Despite a strong cash position and dividend payout, the earnings contraction and subdued revenue may weigh on the stock near-term.